Splice Bio, a CataloniaBio & HealthTech member, has signed an agreement with the Cystic Fibrosis Foundation in the United States to develop new adeno-associated viruses (AAV) to treat cystic fibrosis. 

The biotechnology firm, based at the Barcelona Science Park, will receive €282,000 in funding and collaborate with the foundations' Therapeutics Lab to advance its proprietary third-generation platform to modify delivery vehicles for gene therapy and better target specific cells in patients' lungs.

The Cystic Fibrosis Foundation is a world leader in research to find a cure to this rare disease that affects over 70,000 people around the world. Each year, roughly 1,000 new cases are diagnosed, 75% of which are in patients around 2 years old.

Splice Bio investors include the funds Ysios Capital, Asabys Partners and Caixa Capital Risc.

More information

Photo: Miquel Vila-Perelló, co-founder and CEO of Splice Bio.

You may also be interested in:

• ProteoDesign announces new investment led by Ysios Capital and rebrands as Splice Bio
• ProteoDesign secures a €1.7M financing round for immunotherapy against cancer